The Impact of Gilteritinib on Overall Survival of Adult Patients with FLT3 Positive Acute Myeloid Leukemia: A Systematic Review.

ABSTRACT:

Background

Gilteritinib, an effective and selective inhibitor of the FLT3 gene, was developed to address the challenges posed by relapsed or refractory acute myeloid leukemia (AML) patients who often encounter limited treatment options and poor prognoses with salvage chemotherapy.

Aim

This systematic review aims to explore the progression of interventional research and consolidate existing evidence on the clinical effectiveness of gilteritinib as a monotherapy or combination therapy in improving overall survival among adults experiencing a recurrence or resistance to treatment for FLT3-positive AML patients.

Methods

A comprehensive search strategy, utilizing Medical Subject Headings (MeSH) and non-MeSH terms was conducted across Pubmed, EMBASE, Cochrane, and Web of Sc

SUBMITTER: Gupta SV 

PROVIDER: S-EPMC11618817 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature